-
Fidaxomicin is preferred over vancomycin for both initial and recurrent cases. Bezlotoxumab is recommended in many cases of recurrent infection and initial infection in patients at high risk of recurrence.
-
The occurrence of myocarditis after receipt of COVID-19 mRNA vaccines is most frequent in young males and generally is benign, with rapid resolution with only supportive care. Careful analysis indicates that the benefit of vaccination outweighs the risk in all groups for whom the vaccine is recommended — including young males.
-
Multisystem inflammatory syndrome in children (MIS-C) can be a devastating post-COVID-19 complication, but treatment seems effective. High-dose steroids and intravenous immune globulin (IVIG) are commonly used, although new studies give conflicting findings as to whether it is best to use both treatments together.
-
Differences in outcomes and responses to treatment in diverse populations often have been attributed to biological factors. However, standardized treatment can tell a divergent story, one in which parameters, such as geographic location and financial status, play a significant role in how a person responds. This underscores the importance of a diverse study population in clinical trials, researchers say.
-
Contemplating death can be uncomfortable, but by planning ahead, researchers can find peace in knowing their life’s work continues beyond their physical presence.
-
In an updated policy statement, the American Society for Reproductive Medicine says transgender status should not prevent a patient from accessing fertility preservation. Further, reproductive services should be offered to all interested transgender or nonbinary individuals, barring other disqualifying factors (based on empirical evidence as opposed to bias or stereotypes).
-
The MENDS2 trial found that dexmedetomidine, when used for light sedation, had outcomes similar to those for propofol.
-
A shorter program could be more useful for smaller universities that may not have the resources available to implement a longer program.
-
These two trials had disparate findings with respect to interleukin-6 inhibition, with REMAP-CAP showing a benefit and COVACTA showing none.
-
In this retrospective analysis of COVID-19 patients hospitalized with cytokine storm, the use of corticosteroids combined with tocilizumab was associated with superior survival when compared to no immunomodulatory treatment; a combination of corticosteroids and anakinra; or corticosteroids, tocilizumab, or anakinra alone. Patients who received corticosteroids, either alone or in combination with anakinra, also experienced lower hospital mortality compared to no treatment.
